Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful prescription treatments in settings that operate largely outside state ...

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

By Leah Douglas and Siddhi Mahatole Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it would take ...

Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine ...

Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies ...

Shares of NVO are on the move again premarket, soaring another 7% on the news, while HIMS shares are down 16% in early trading. However, questions continue to surface about cheaper medication ...

Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs that companies such as Hims & Hers and other ...

Sen. Tom Cotton, R-Ark., warned that up to 1.5 million Americans may be using weight loss medications with potentially dangerous Chinese ingredients.

Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift ...